Alternating Treatment with Didanosine and Zidovudine versus Either Drug Alone for the Treatment of Advanced HIV Infection. The Alter Study

References

• Fischl M A, Richman D D, Grieco M H, Gottlied M S, Volberding P A, Laskin O L, Leedom J M, Groopman J E, Mildvan D, Schooley R T, Jackson G G, Durack D T, King D. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–191
   PubMed Web of Science ®Google Scholar
• Lundgren J D, Philips A N, Pedersen C, Clumeck N, Gatell J M, Johnson A M, Ledergerber B, Vella S, Nielsen J O. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994; 271: 1088–1092
   PubMedGoogle Scholar
• Larder B H, Darby G, Richmann D D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prologed therapy. Science 1989; 243: 1731–1734
   PubMed Web of Science ®Google Scholar
• Dolin R, Amato D A, Fischl M A, Pettinelli C, Beltanqady M, Liou S H, Brown M J, Cross A P, Hirsch M S, Hardy W D. Zidovudine compared with didanosine in patients with advanced HIV infection and little or no previous experience with zidovudine. Arch Intern Med 1995; 155: 961–974
   PubMed Web of Science ®Google Scholar
• Kahn J O, Lagakos S W, Richman D D, Cross A, Pettinelli C, Liou S H, Brown M, Volberding P A, Crumpacker C S, Beall G, Sacks H S, Merigan T C, Beltangady M, Smaldone L, Dolin R. and the NIAID AIDS Clinical Trials Group. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581–587
   PubMed Web of Science ®Google Scholar
• Skowron G, Bozzette S A, Lim L, Pettinelli C, Schaumburg H, Arezzo J, Fischl M A, Powderly W G, Gocke D J, Richman D D, Pottage J C, Antoniskis D, McKinley G F, Hyslop N E, Ray G, Simon G, Reed N, LoFaro M L, Uttamchandani R B, Gelb L D, Sperber S J, Murphy R L, Leedom J M, Grieco M H, Zachary J, Hirsch M S, Spector S A, Bigley J, Soo W, Merigan T C. Alternation and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993; 118: 321–330
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Lietzau J A, Nguyen B-Y, Brawley O W, Pluda J M, Saville M W, Wyvill K M, Steinberg S M, Agbaria R, Mitsuya H, Broder S. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169: 9–17
   PubMedGoogle Scholar
• Yarchoan R, Perno C F, Thomas R V, Klecker R W, Allain J P, Wills R J, McAtee N, Fischl M A, Dubinsky R, McNeely M C, Mitsuya H, Pluda J M, Lawley T J, Leuther M, Safai B, Collins J M, Myers C E, Broder S. Phase I studies of 2', 3'-dideoxycy-tidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76–81
   PubMed Web of Science ®Google Scholar
• Bozzette S A, Richman D D. Salvage therapy for zidovudine-in-tolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytinde. Am J Med 1990; 88, Suppl 5B: 24S-6S
   PubMedGoogle Scholar
• Nielsen C, Brun L, Pedersen C, Mathiesen L, Gerstoft J. Development of resistance to AZT and ddI in HIV from patients in AZT, ddI and alternating AZT/ddi treatment. AIDS 1996; 10: 625–633
   PubMedGoogle Scholar
• Yeni P. Preliminary results of the European/Australian delta trial: Based on data up to 31st May, 1995. Abstract. Fifth European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen Sept. 26–29, 1995. Lancet 1996; 348: 283–291
   PubMedGoogle Scholar
• Hammer S M, Katzenstein D A, Hughes M D, Gundacker H, Schooley R T, Haubrich R H, Henry W K, Lederman M M, Phair J P, Niu M, Hirsch M S, Merigan T C. and the AIDS Clinical Trials Group Study 175 Study Team. Nucleoside monotherapy (MT) vs. combination therapy (CT) in HIV infected adults: a randomised, double-blind, placebo-controlled trial in persons with CD4 cell counts 200–500/mm3. Abstract. Fifth European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen Sept. 26–29, 1995. N Engl J Med 1996; 335: 1081–1090
   PubMed Web of Science ®Google Scholar
• Spruance S L, Pavia A T, Peterson D, Berry A, Pollard R, Patterson T F, Frank I, Remick S C, Thompson M, MacArthur R D, Morey G E, Ramirez-Ronda C H, Bernstein B M, Sweet D E, Crane L, Peterson E A, Pachucki C T, Green S L, Brand J, Rios A, Dunkle L M, Cross A, Brown M J, Ingraham P, Gugliotti R, Schindzielorz H, Smaldone L. for the Bristol-Myers Squibb AI454–010 Study Group. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while reviewing zidovudine. Ann Intern Med 1994; 120: 360–368
   PubMed Web of Science ®Google Scholar
• ddI Iberian Study Group. Efficacy and safety of didanosine (ddI) vs. zidovudine (ZDV) in patients with HIV infection no longer benefiting from ZDV therapy. Abstract 037, 4th European Conference on Clinical Aspects and Treatment of HIV Infection. Milan 1994
   Google Scholar
• Montaner J SG, Schechter M T, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg M A. and the Canadian HIV Trials Network Protocol 002 Study Group. Didanosine compared with continued zidovudine therapy for HIV infected patients with 200 to 500 CD4 cells/mm3. Ann Intern Med 1995; 123: 561–571
   PubMed Web of Science ®Google Scholar